The LPAR2 inhibitor suppressed the proliferative and migration abilities of GC cell line SGC-7901 through the LPAR2/Gq11/p38 pathway, suggesting that LPAR2 might be a potential target for GC treatment [112]. Here, MAPK14 is linked to gastric cancer.